TB Diagnostics Pipeline: New Tools & Opportunities to Improve Access to Testing
On May 15, join Treatment Action Group for a webinar on the TB Diagnostics Pipeline: New Tools & Opportunities to Improve Access to Testing.
NOW Is the Time for Hepatitis C Virus Elimination
Hepatitis C-related liver diseases continue to kill an estimated 15,000 people per year in the United States, despite the availability of an effective cure.
ACTIVISM DELIVERS UNPRECEDENTED VICTORIES IN TB TESTING AND TREATMENT ACCESS
Three recent announcements of tuberculosis (TB) medicine and diagnostics price reductions access will enable millions more people to receive TB preventive therapy, and to be tested and treated for TB. Announced alongside the United Nations General Assembly High-Level Meeting on Tuberculosis (TB) in September, these victories across the cascade of TB care were the result of years of targeted, spirited, and informed mobilization from the TB community.
TAG Applauds Price Reduction of Molbio’s Truenat Diagnostics for Tuberculosis
Treatment Action Group (TAG) applauds Molbio’s agreement with the Stop TB Partnership, USAID, and the Global Fund to reduce the price of Truenat diagnostic tests for tuberculosis (TB) from US$9 per test to $7.90 per test and to provide quality service and maintenance of Truenat testing instruments globally.
Roundtable on Access to Multi-disease Molecular Diagnostics
On June 2, 2022, Treatment Action Group (TAG) and Médecins Sans Frontières (MSF) hosted a Roundtable on Access to Multi-disease Molecular Diagnostics, which brought together country program representatives, donors, members of civil society, and other global health actors to: Identify…
Test and Treat COVID-19: An Advocate’s Introduction to SARS-CoV-2 Rapid Diagnostic Testing
All people have the right to know their COVID-19 status and to be able to use that information to protect themselves, their families, and their communities. Rapid antigen tests can be used at home or in informal settings to reliably and quickly detect cases of COVID-19, to guide decisions on interventions such as self-isolation, contact tracing, and antiviral treatment.
Community-led Monitoring for Access to Tuberculosis Screening and Diagnostic Testing
People at risk of tuberculosis (TB) have a right to TB screening and diagnostic testing in accordance with the standard of care recommended by the World Health Organization (WHO). Yet, many countries with high burdens of TB have limited uptake…
Statement from TAG’s TB Project on Today’s WHO Global TB Report
Today's Global TB Report from WHO confirms our worst expectations for how COVID-19 has set back the global TB response. The pandemic has reversed an entire generation of progress. The first year-on-year increase in TB deaths since 2005 is devastating.
Realizing Returns on U.S. Government Investments in GeneXpert Diagnostic Technologies
GeneXpert diagnostic tests are essential tools in the struggle against COVID-19, tuberculosis, HIV, viral hepatitis, and other diseases. This brief outlines actionable steps the U.S. government can take to hold Cepheid accountable for transparent, fair, and equitable pricing of GeneXpert tests.
Time for $5 Coalition Statement: Cepheid’s Updated GeneXpert Pricing Does Not Address Country Needs
The Time for $5 Coalition, comprised of over 150 civil society organizations globally, calls out Cepheid for the company’s insufficient and self-serving GeneXpert pricing packages for low- and middle-income countries (LMICs), announced May 6, 2021.